Fosamax Legal & Patent Challenges: What Every Woman Taking Alendronate Should Know

Why the Regulatory History of Fosamax Matters to You

The legal and regulatory battles surrounding Fosamax are not courtroom abstractions. They determined what warnings appear on your pill bottle, whether you can afford a generic, and what your prescriber is legally obligated to tell you before you start. If you are a postmenopausal woman managing osteoporosis, or a woman in perimenopause who has just received a DEXA scan showing low bone density, understanding this history gives you a clearer picture of what the evidence actually says and where gaps remain.

Merck launched Fosamax in the United States in September 1995, making it the first oral bisphosphonate approved for postmenopausal osteoporosis. The drug's mechanism, inhibiting osteoclast-mediated bone resorption, was already understood, but the scale of its commercial success was not anticipated. By the mid-2000s, annual global sales exceeded four billion dollars. That scale also meant that rare adverse events, invisible in pre-approval trials, became visible in post-market surveillance, and they triggered the regulatory and legal conflicts that followed.

The FDA Approval Pathway and Early Label

What the original 1995 label covered

The initial FDA approval covered alendronate 10 mg daily for treatment of postmenopausal osteoporosis. The label required that women take the tablet first thing in the morning with a full glass of plain water, remain upright for at least 30 minutes, and eat or drink nothing else during that window. These instructions existed because alendronate has poor oral bioavailability, estimated at less than 1% when taken with food, and because esophageal irritation emerged as a real clinical problem in early post-approval experience.

Merck then sought, and received, FDA approval for a 70 mg once-weekly formulation in 2000. The weekly dose became the dominant prescribing pattern because adherence improved substantially compared with daily dosing, and the total monthly drug exposure was bioequivalent.

Expanding indications across the 1990s and 2000s

The FDA granted Merck additional indications in sequence. These included prevention (rather than treatment) of postmenopausal osteoporosis at the lower 5 mg daily dose in 1997, glucocorticoid-induced osteoporosis in men and women in 1999, and male osteoporosis in 2000. Each expansion required its own sNDA (supplemental New Drug Application) with supporting trial data.

For women specifically, the Fracture Intervention Trial (FIT) published in JAMA in 1998 was the most consequential dataset. FIT randomized 2,027 postmenopausal women with at least one existing vertebral fracture and low bone mass to alendronate or placebo and followed them for three years. Women assigned to alendronate had a 47% relative risk reduction in hip fracture and a 55% reduction in clinical vertebral fracture. FIT remains the bedrock efficacy evidence that still appears in current prescribing guidelines from ACOG and The Menopause Society.

Patent Disputes and the Arrival of Generics

Merck's primary patent and the 2008 expiration

Merck held several overlapping patents on Fosamax covering the compound, the crystalline form, and the once-weekly dosing regimen. The primary composition-of-matter patent expired in February 2008. In the lead-up to that date, at least six generic manufacturers had filed Abbreviated New Drug Applications (ANDAs) under the Paragraph IV certification pathway, asserting that Merck's remaining patents were either invalid or not infringed.

Merck filed patent-infringement suits against each filer, as is standard under the Hatch-Waxman Act. The 30-month automatic stay blocked generic entry while litigation proceeded. Merck ultimately did not prevail on all patent claims, and multiple generic alendronate products reached pharmacy shelves in 2008. The price of a month's supply of alendronate fell by roughly 90% within 18 months of generic entry, a change with direct implications for postmenopausal women on fixed incomes who had previously rationed doses or discontinued treatment because of cost.

Why the once-weekly dosing patent mattered

One of Merck's more aggressive patent positions involved the 70 mg once-weekly regimen itself. Merck argued that the concept of weekly dosing was a distinct and patentable innovation. Generic manufacturers contested this, and the courts eventually ruled against Merck's broadest claims on the dosing-interval patents. The outcome was that generics could be labeled for weekly dosing, which mattered enormously because that is the formulation most women are prescribed.

Major Label Changes: Atypical Femur Fractures and Osteonecrosis

The 2010 atypical femur fracture warning

Post-market surveillance and published case series identified a pattern of unusual, low-energy femur fractures occurring in long-term bisphosphonate users. These fractures typically occur in the subtrochanteric or diaphyseal shaft, and they often begin as stress reactions with a characteristic radiographic "beaking" on the lateral cortex. The FDA reviewed the evidence and in October 2010 required Merck and all generic manufacturers to add a new warning to the Fosamax label specifically addressing atypical femoral fractures.

The absolute risk is small. A 2011 analysis published in the New England Journal of Medicine estimated the incidence of atypical femoral fractures at approximately 2 cases per 10,000 patient-years among women with five or fewer years of bisphosphonate use, rising to 78 per 10,000 patient-years among women with nine or more years of use. The hip fracture rate prevented by alendronate substantially exceeds this risk in women with established osteoporosis, but the calculation changes for women with osteopenia who have a lower baseline fracture risk. This tradeoff is exactly the kind of individualized risk discussion your clinician should walk through with you before you decide on duration of therapy.

Osteonecrosis of the jaw

The FDA also required updated labeling around osteonecrosis of the jaw (ONJ), a rare condition in which jaw bone fails to heal, typically after dental extraction or other oral surgery. ONJ risk is substantially higher in patients receiving intravenous bisphosphonates for cancer-related bone disease than in those taking oral alendronate for osteoporosis. A 2015 systematic review estimated ONJ risk in oral bisphosphonate users at roughly 1 in 10,000 to 1 in 100,000 patient-years, far lower than the initial media coverage implied.

The practical guidance that emerged from these label changes was not to stop dental care, but to coordinate timing. Women on alendronate are advised to complete necessary dental work before starting bisphosphonate therapy when possible, or to inform their dentist of their medication so that prophylactic measures can be taken.

A useful way to think about the label-change timeline is as a three-phase arc that applies to many blockbuster drugs approved before the FDA Amendments Act of 2007 strengthened post-market surveillance requirements. Phase one is pre-approval efficacy: alendronate demonstrated clear fracture reduction in FIT. Phase two is early post-market signal detection: esophageal events and the first ONJ reports, addressed by labeling updates through the early 2000s. Phase three is long-duration surveillance: atypical femur fractures, which only became visible after cohorts of women had been on the drug for seven or more years. Women who started alendronate in the late 1990s and stayed on it without a drug holiday were the sentinel group for phase three signals.

The Supreme Court Litigation and What It Means for Generic Warnings

Mutual Pharmaceutical Co. V. Bartlett (2013)

The most legally significant case touching alendronate's regulatory history is not a Fosamax-specific case but one that shaped the liability field for all generic drugs. In Mutual Pharmaceutical Co. V. Bartlett (2013), the Supreme Court ruled 5-4 that federal law preempts state-law design-defect claims against generic drug manufacturers because generics are required to use the same label as the brand-name drug and cannot independently change their formulation.

The practical consequence: if you were harmed by a generic drug and the brand-name company's label already included a warning for that harm, you may have limited recourse against the generic manufacturer under state tort law. For alendronate specifically, women who experienced atypical femur fractures before the 2010 label update faced a more viable litigation window than those injured after the warning was added.

Fosamax ONJ litigation against Merck

Merck faced thousands of individual lawsuits from women who alleged they developed osteonecrosis of the jaw after taking Fosamax and that Merck had failed to warn them adequately and in a timely way. The cases were consolidated into a multidistrict litigation (MDL) in the District of New Jersey. In 2014, a federal judge dismissed most of the MDL cases, finding that Merck had updated its label when evidence supported the need to do so and that the updated label was adequate. Some cases proceeded to trial and individual settlements were reached, but Merck did not face a single large class-action judgment. The dismissal of the MDL was a significant moment in pharmaceutical product-liability law, reinforcing the "learned intermediary" doctrine under which a drug company's duty to warn runs to the prescribing physician rather than directly to the patient.

For women, the practical takeaway is this: the regulatory system did identify and act on these risks, but with a lag. If you have been on alendronate for more than five years, a structured conversation with your prescriber about drug holidays and fracture risk reassessment is not a legal precaution. It is standard clinical care, endorsed by The Menopause Society's 2023 position statement on osteoporosis management.

Pregnancy, Lactation, and Contraception: A Required Reading Section

Alendronate is contraindicated in pregnancy. If there is any chance you could become pregnant, you should not take this drug without serious discussion with your clinician and reliable contraception in place.

Animal and human data

Alendronate carries FDA Pregnancy Category C based on pre-2015 labeling conventions (current labeling uses the PLLR narrative format). In animal studies, bisphosphonates caused fetal harm at doses comparable to human therapeutic exposure, including reduced fetal weight and skeletal abnormalities. Human data are limited to case reports and small registries. Bisphosphonates are incorporated into bone and have a skeletal half-life measured in years, meaning that drug remains in your skeleton long after you stop taking it. Fetal exposure from this skeletal reservoir is a theoretical concern even if you stop alendronate before conception.

A 2010 review in Osteoporosis International identified 51 pregnancies with bisphosphonate exposure and found no consistent pattern of malformation, but the sample size is too small to rule out a signal. Women with premenopausal osteoporosis or glucocorticoid-induced bone loss who are in their reproductive years should have an explicit conversation about this uncertainty.

Lactation

It is unknown whether alendronate is excreted in human breast milk. The drug's high protein binding and very low oral bioavailability suggest that infant exposure would be minimal even if trace amounts appeared in milk, but no adequate human lactation studies exist. The prescribing information advises caution. Women who are breastfeeding and have urgent clinical need for fracture-risk reduction should discuss alternatives, including calcium, vitamin D optimization, and in some cases denosumab (which has its own lactation data limitations), with their prescriber.

Contraception requirement

Alendronate is not formally classified as a teratogen in the way that thalidomide or isotretinoin are, meaning there is no mandatory iPLEDGE-type contraception program. Women of reproductive age taking alendronate for premenopausal indications (such as glucocorticoid-induced osteoporosis or premenopausal osteoporosis) should use reliable contraception and should discuss a planned pregnancy timeline with their clinician well in advance, ideally 12 or more months before attempting conception, given the drug's prolonged skeletal retention.

Who This Drug Is Right For, and Who Should Think Twice

Women most likely to benefit

Alendronate is most clearly indicated for postmenopausal women with a DEXA T-score at or below negative 2.5 (osteoporosis range) or a T-score between negative 1.0 and negative 2.5 (osteopenia) combined with a 10-year FRAX hip fracture probability at or above 3% or a major osteoporotic fracture probability at or above 20%, per NOF/ASBMR thresholds. Women with a prior fragility fracture are also strong candidates regardless of T-score.

Women taking long-term glucocorticoids (prednisone 5 mg or more daily for three or more months) represent a separate high-benefit group, and ACOG recommends considering bisphosphonate therapy in this context regardless of menopausal status.

Women who should pause before starting

Women who are pregnant, planning pregnancy within the next 12 months, or breastfeeding should discuss alternatives with their clinician. Women with active upper GI disease, esophageal stricture, or an inability to sit or stand upright for 30 minutes after dosing should consider alternative agents (denosumab, zoledronic acid, or raloxifene depending on their profile). Women who have already been on alendronate for five or more years without a DEXA-based reassessment should ask their clinician whether a drug holiday is appropriate. A 2021 analysis in JAMA Internal Medicine found that continuing bisphosphonates beyond five years in low-risk women did not significantly reduce fracture rates compared to stopping, while atypical femur fracture risk continued to accumulate.

Life-stage differences

Reproductive years. Premenopausal women are rarely started on alendronate unless they have documented bone loss from glucocorticoids, anorexia-related bone disease, or true premenopausal osteoporosis confirmed on DEXA. The evidence base in this group is thin, as most trials enrolled postmenopausal women. This is an explicit evidence gap.

Perimenopause. Bone loss accelerates sharply in the two to three years before the final menstrual period and the two years after, driven by estrogen withdrawal. Menopausal hormone therapy addresses both the bone loss and vasomotor symptoms simultaneously and is often the preferred first-line approach in women under 60 who are good candidates. Alendronate may be layered in or substituted when hormone therapy is contraindicated or declined.

Postmenopause. This is the population with the strongest evidence base. FIT, the FLEX extension trial, and the HORIZON key fracture trial collectively define the risk-benefit calculation for this group. Duration of therapy, drug holidays, and sequential therapy with anabolic agents (teriparatide, romosozumab) after a prolonged bisphosphonate course are active clinical questions.

Post-menopause with prior breast cancer. Women who have had hormone-receptor positive breast cancer and are on aromatase inhibitors face accelerated bone loss as a drug side effect. ASCO clinical practice guidelines recommend bone-protective therapy, and alendronate is one of the options, though zoledronic acid has the additional benefit of potential anti-tumor activity in some analyses.

The Evidence Gap Women Deserve to Know About

Women have been the majority of alendronate trial participants, which is a genuine strength of this evidence base compared with many other drug classes. However, several important gaps persist.

Black women have higher rates of clinical fracture underestimation on FRAX because the tool uses population-level adjustments that may not capture individual bone geometry or fall risk. A 2020 analysis in the Journal of Bone and Mineral Research found that FRAX systematically underestimates fracture risk in Black women with low bone density. Whether alendronate's fracture reduction is equally effective across racial groups has not been tested in adequately powered subgroup analyses.

Women with PCOS, who already face altered metabolic bone turnover from androgen excess and insulin resistance, represent another understudied group. The effect of alendronate in women with PCOS-related bone phenotypes is extrapolated from the general postmenopausal population, not directly studied.

Practical Checklist: Questions to Ask Before You Fill Your Prescription

Before you start, continue, or stop alendronate, bring these specific questions to your prescriber.

• What is my FRAX 10-year probability, and which threshold are you using to recommend treatment?
• Do I need a baseline dental exam before starting?
• How long do you plan to continue this drug before reassessing with a DEXA scan?
• If I have been on alendronate for five or more years, what is my current atypical femur fracture risk relative to my ongoing hip fracture benefit?
• If I am perimenopausal, have we discussed whether menopausal hormone therapy might address both my bone loss and my symptoms at the same time?
• If I am or might become pregnant in the next year, what is the plan?